Positive HER2 status - Is it a discriminating factor for disease outcome in steroid receptor-positive early breast cancer patients treated with adjuvant endocrine therapy only?

被引：1
|
作者：
Susnjar, S. [1 ]
Vujasinovic, T. [2 ]
Abu Rabi, Z. [2 ]
Neskovic-Konstantinovic, Z. [1 ]
Milovanovic, Z. [3 ]
Jovanovic, D. [3 ]
Gavrilovic, D. [4 ]
Borojevic, N. [5 ]
机构：
[1] Inst Oncol & Radiol Serbia, Dept Med Oncol, Belgrade, Serbia
[2] Inst Oncol & Radiol Serbia, Expt Oncol Lab, Belgrade, Serbia
[3] Inst Oncol & Radiol Serbia, Dept Pathol, Belgrade, Serbia
[4] Inst Oncol & Radiol Serbia, Ctr Data, Belgrade, Serbia
[5] Inst Oncol & Radiol Serbia, Dept Radiotherapy, Belgrade, Serbia
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70187-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [21] Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer
    Fagnani, Francis
    Colin, Xavier
    Arveux, Patrick
    Coudert, Bruno
    Misset, Jean-Louis
    BULLETIN DU CANCER, 2007, 94 (7-8) : 711 - 720
  • [22] Adjuvant Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer in Premenopausal Patient: Understanding the Data
    Saha P.
    Fleming G.F.
    Current Breast Cancer Reports, 2015, 7 (4) : 183 - 189
  • [23] Outcome of adjuvant chemotherapy in elderly patients with early-stage, hormone receptor-positive, HER-2-negative breast cancer
    Ma, Sung Jun
    Oladeru, Oluwadamilola T.
    Singh, Anurag K.
    BREAST JOURNAL, 2020, 26 (10): : 2026 - 2030
  • [24] Neoadjuvant endocrine therapy helps identify HER2 up-regulation in patients with hormone receptor-positive HER2-negative breast cancer
    Chaudhary, Lubna N.
    Jorns, Julie M.
    Cheng, Yee Chung
    Kamaraju, Sailaja
    Gonyo, Mary Beth
    Kong, Amanda
    Patten, Caitlin
    Yen, Tina
    Cortina, Chandler
    Carson, Ebony
    Johnson, Nedra
    Bergom, Carmen
    Banerjee, Anjishnu
    Wang, Yu
    Chitambar, Christopher R.
    Rui, Hallgeir
    CANCER RESEARCH, 2021, 81 (04)
  • [25] Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion
    Caputo, Roberta
    Buono, Giuseppe
    Lauro, Vincenzo Di
    Cianniello, Daniela
    Arx, Claudia Von
    Pensabene, Matilde
    Pagliuca, Martina
    Pacilio, Carmen
    Rella, Francesca Di
    Verrazzo, Annarita
    Martinelli, Claudia
    Nuzzo, Francesco
    De Laurentiis, Michelino
    FUTURE ONCOLOGY, 2023, 19 (24) : 1695 - 1708
  • [26] Clinical Significance of Progesterone Receptor and HER2 Status in Estrogen Receptor-Positive, Operable Breast Cancer with Adjuvant Tamoxifen: Consistent Prognostic Impact of HER2 Status Over Time
    Moon, Y. W.
    Park, S.
    Sohn, J. H.
    Kang, D. R.
    Koo, J. S.
    Park, H. S.
    Chung, H. C.
    Park, B-W
    CANCER RESEARCH, 2010, 70
  • [27] Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
    Pegram, Mark
    Jackisch, Christian
    Johnston, Stephen R. D.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [28] Which Patients with Estrogen Receptor-Positive Early Breast Cancer Should Be Treated with Adjuvant Chemotherapy?
    Chiuri, Vincenzo Emanuele
    Lorusso, Vito
    ONCOLOGY, 2009, 77 : 18 - 22
  • [29] Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
    Mark Pegram
    Christian Jackisch
    Stephen R. D. Johnston
    npj Breast Cancer, 9
  • [30] Delay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast Cancer
    Vaughn, Jennifer E.
    Ammerman, Chesley
    Lustberg, Maryam B.
    Bickel, Warren K.
    Stein, Jeffrey S.
    HEALTH PSYCHOLOGY, 2021, 40 (06) : 398 - 407
12345